Cargando…

Virus-induced CXCL10-CXCR3 positive feedback loop via astrocytes is critical for maintaining chronic inflammatory lesions in HAM/TSP

Detalles Bibliográficos
Autores principales:	Sato, Tomoo, Ando, Hitoshi, Tomaru, Utano, Yoshida, Mari, Utsunomiya, Atae, Yamauchi, Junji, Araya, Natsumi, Yagishita, Naoko, Coler-Reilly, Ariella, Jacobson, Steven, Yamano, Yoshihisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042440/ http://dx.doi.org/10.1186/1742-4690-11-S1-O25

Ejemplares similares

Clinical subtype of HAM/TSP based on clinical course and laboratory findings
por: Yamano, Yoshihisa, et al.
Publicado: (2011)

CXCL10 and neopterin in CSF are candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis
por: Yamano, Yoshihisa, et al.
Publicado: (2014)

Humanized anti CCR4 antibody KW0761 targets HTLV-1 infected CD4+ CCR4+ and CD8+CCR4+ T cells to treat HAM/TSP
por: Yamano, Yoshihisa, et al.
Publicado: (2015)

The plasticity of HTLV-1 infected CD4+CD25+CCR4+ T-cells through HTLV-1 tax in HAM/TSP
por: Araya, Natsumi, et al.
Publicado: (2011)

Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan
por: Tsutsumi, Shuntaro, et al.
Publicado: (2019)

CSF CXCL10, CXCL9, and Neopterin as Candidate Prognostic Biomarkers for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
por: Sato, Tomoo, et al.
Publicado: (2013)

HTLV-1 Tax induces Th1 master regulator T-bet and thus IFN-γ in CD4+CCR4+ T-cells of virus-associated myelopathy patients
por: Araya, Natsumi, et al.
Publicado: (2015)

Nation-wide epidemiological study in Japan on HTLV-1 associated myelopathy/tropical spastic paraparesis using HAM-net, a novel patient registration system
por: Coler-Reilly, Ariella LG, et al.
Publicado: (2014)

Evaluation of clinical outcome measures for HAM/TSP
por: Kikuchi, Takayuki, et al.
Publicado: (2015)

Characteristics of HAM/TSP after kidney transplantation from HTLV-1 positive living donors
por: Kimura, Miyuna, et al.
Publicado: (2015)

Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net)
por: Coler-Reilly, Ariella L. G., et al.
Publicado: (2016)

Human T-Lymphotropic Virus Type 1 (HTLV-1) and Regulatory T Cells in HTLV-1-Associated Neuroinflammatory Disease
por: Araya, Natsumi, et al.
Publicado: (2011)

HAM-net national patient registration system reveals details of how Japanese patients with HTLV-1-associated myelopathy/tropical spastic paraparesis progress over time
por: Coler-Reilly, Ariella, et al.
Publicado: (2015)

Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
por: Tamaki, Keiko, et al.
Publicado: (2019)

Patient satisfaction survey for HAM-net registrants
por: Sato, Kentaro, et al.
Publicado: (2015)

Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient
por: Takeda, Reina, et al.
Publicado: (2020)

Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019
por: Araujo, Abelardo, et al.
Publicado: (2021)

Wish list: which biomarker studies in HAM/TSP should be funded by the God of all trial funds?
por: Yamano, Yoshihisa
Publicado: (2014)

HAM/TSP introduction: systematic review of HAM/TSP clinical trials
por: Anderson, Rebecca, et al.
Publicado: (2014)

Correlation of increased CXCL13 with intrathecal humoral immune responses to HTLV-1 in CSF of patients with HAM/TSP
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2014)

HAM/TSP in relatives of HAM/TSP cases and in relatives of asymptomatic HTLV-1 carriers
por: Alvarez, Carolina, et al.
Publicado: (2014)

Molecular and clinical analyses of HTLV-1 subgroups associated with the risk of developing HAM/TSP.
por: Saito, Mineki, et al.
Publicado: (2015)

Managing HAM/TSP with Fampridine
por: Menna-Barreto, M Marcio
Publicado: (2014)

Abnormally High Levels of Virus-Infected IFN-γ(+)CCR4(+)CD4(+)CD25(+) T Cells in a Retrovirus-Associated Neuroinflammatory Disorder
por: Yamano, Yoshihisa, et al.
Publicado: (2009)

Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity
por: Sato, Tomoo, et al.
Publicado: (2018)

Biomarker to predict treatment response in patients with HTLV-1 associated myelopathy/Tropical spastic paraparesis (HAM/TSP)
por: Tamaki, Keiko, et al.
Publicado: (2015)

Clinical course of neurogenic bladder dysfunction in human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: a nationwide registry study in Japan
por: Iijima, Naoki, et al.
Publicado: (2021)

Possibility of γδ T cell immunotherapy for HTLV-1-infected individuals
por: Sato, Tomoo, et al.
Publicado: (2011)

Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM/TSP
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2017)

HTLV-1 proviral load of HAM/TSP patients according to new diagnostic criteria of HAM/TSP
por: Grassi, Maria F R, et al.
Publicado: (2011)

Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
por: Enose‐Akahata, Yoshimi, et al.
Publicado: (2021)

Clinical features of familial HAM/TSP
por: Nozuma, Satoshi, et al.
Publicado: (2014)

HTLV-1 proviral load as an indicative marker of HAM/TSP: a systematic review of studies of patients with HAM/TSP
por: Bassi, Shiva Shaan, et al.
Publicado: (2014)

Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis
por: Yamakawa, Natsuko, et al.
Publicado: (2020)

Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy
por: Kimura, Miyuna, et al.
Publicado: (2022)

Recent epidemiologic trends of HAM/TSP in Japan
por: Matsuzaki, Toshio, et al.
Publicado: (2011)

HAM/TSP and major depression: the role of age
por: Boa-Sorte, Ney, et al.
Publicado: (2015)

Proteomic profiling of HTLV-1 infected T-cells for the identification of potential biomarkers and therapeutic targets for HTLV-1 associated myelopathy/ tropical spastic paraparesis and adult T-cell leukemia
por: Ueda, Koji, et al.
Publicado: (2011)

Change in timed walk as primary outcome measure of treatment response in HAMLET-P: HAM/TSP MuLticentre Efficacy trial-Prednisolone
por: Martin, Fabiola, et al.
Publicado: (2014)

Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3ueaoib5ggvk3fbqfehru101jf